Physician profile
Wen Long
NPI 1225117096
$2,421.88
in general payments reported to CMS, 2019-2025
12 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $1,321 · 2023: $27.57 · 2024: $212 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,566.41 | 2021-2022 | |
| Abbvie INC. | $506.06 | 2022-2025 | |
| Gilead Sciences, INC. | $101.21 | 2025 | |
| Boston Scientific Corporation | $51.82 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Ipsen Biopharmaceuticals, INC | $30.65 | 2025 | Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $28.31 | 2024 | Livtencity |
| Mallinckrodt Hospital Products INC. | $27.16 | 2024 | Terlivaz |
| Madrigal Pharmaceuticals | $26.83 | 2024 | Resmetirom |
| Eton Pharmaceuticals, INC. | $25.56 | 2025 | Galzin, Carglumic Acid, Betaine Anhydrous |
| Mirum Pharmaceuticals, INC. | $22.38 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $20.12 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.37 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.